SAN JOSE, Calif., March 12, 2021 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer and infectious diseases,
announced today that the European Patent Office has issued and
published the first European patent for its novel ovarian cancer
vaccine technology. This technology was invented and
developed at Cleveland Clinic and Anixa is the worldwide
licensee.
The patent is titled, "Ovarian Cancer Vaccines," and the
inventors are Drs. Vincent K. Tuohy,
Suparna Mazumder, and Justin M. Johnson, all of Cleveland Clinic.
Dr. Amit Kumar, President and CEO
of Anixa Biosciences, stated, "We are pleased that the European
Patent Office (EPO) has issued this patent. This ovarian
cancer vaccine has the potential to eliminate one of the deadliest
malignancies in women. Ovarian cancer is often diagnosed
after it has reached Stage 3 or 4, and when it is difficult to
effectively treat. Five-year survival statistics for ovarian
cancer are poor, so if this vaccine is able to eliminate the onset
of ovarian cancer, the impact for women and for our healthcare
system will be tremendous."
"The ovarian cancer vaccine targets a protein (the Extracellular
Domain of the Anti-Mullerian Hormone Receptor 2, AMHR2-ED) that is
expressed only in the ovaries and only in pre-menopausal
women. After menopause, the target protein disappears and is
only seen again when ovarian cancer cells arise. Our vaccine
targets the AMHR2-ED and trains the immune system to destroy these
cancer cells as they arise," said Dr. Vincent Tuohy of the Department of Inflammation
and Immunity at Cleveland Clinic's Lerner Research Institute.
"We are looking forward to our continued alliance with Anixa
Biosciences to further develop this technology."
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutics portfolio includes a cancer immunotherapy program
which uses a novel type of CAR-T, known as chimeric endocrine
receptor T-cell (CER-T) technology, and a Covid-19 therapeutics
program focused on inhibiting certain viral protein function.
The company's vaccine portfolio includes a vaccine to prevent
breast cancer, and specifically triple negative breast cancer
(TNBC), the most deadly form of the disease, and a vaccine to
prevent ovarian cancer. These vaccine technologies focus on
immunizing against specific proteins that have been found to be
expressed in certain forms of cancer. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You
are cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
release.
Investor contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Media contact:
Sherry Ash
anixapress@gmail.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-and-publication-of-european-patent-for-ovarian-cancer-vaccine-technology-301246332.html
SOURCE Anixa Biosciences, Inc.